A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization

References

• Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Kelley RK, Greten TF. Hepatocellular carcinoma—origins and outcomes. New Engl J Med. 2021;385(3):280–282. doi:10.1056/NEJMcibr2106594
   PubMed Web of Science ®Google Scholar
• Dash S, Aydin Y, Widmer KE, et al. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma. 2020;7:45–76. doi:10.2147/JHC.S221187
   Web of Science ®Google Scholar
• Cai X. Laparoscopic liver resection: the current status and the future. Hepatobiliary Surg Nutr. 2018;7(2):98–104. doi:10.21037/hbsn.2018.02.07
   Web of Science ®Google Scholar
• Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–1921. doi:10.1200/JCO.2017.76.0892
   PubMed Web of Science ®Google Scholar
• Geraldes FO. Annual congress of the European Association of nuclear medicine 2021. Lancet Oncol. 2021;22(12):1655. doi:10.1016/S1470-2045(21)00634-3
   Google Scholar
• Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. doi:10.1002/hep.28453
   PubMed Web of Science ®Google Scholar
• Sheng Y, Wang Q, Liu HF, et al. Preoperative nomogram incorporating clinical factors, serological markers and LI-RADS MRI features to predict early recurrence of hepatocellular carcinoma treated with transarterial chemoembolization. Acad Radiol. 2022;30:1288–1297. doi:10.1016/j.acra.2022.10.020
   Web of Science ®Google Scholar
• Katayama K, Imai T, Abe Y, et al. Number of nodules but not size of hepatocellular carcinoma can predict refractoriness to transarterial chemoembolization and poor prognosis. J Clin Med Res. 2018;10(10):765–771. doi:10.14740/jocmr3559w
   Google Scholar
• Liu S, Li H, Guo L, et al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion. Oncologist. 2019;24(4):513–520. doi:10.1634/theoncologist.2018-0305
   PubMed Web of Science ®Google Scholar
• Biolato M, Gallusi G, Iavarone M, et al. Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Hepatol. 2018;17(1):110–118. doi:10.5604/01.3001.0010.7542
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Chon YE, Park H, Hyun HK, et al. Development of a new nomogram including neutrophil-to-lymphocyte ratio to predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancers. 2019;11(4):509. doi:10.3390/cancers11040509
   PubMed Web of Science ®Google Scholar
• Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2014;13:8–17. doi:10.1016/j.csbj.2014.11.005
   PubMed Web of Science ®Google Scholar
• Lee G, Lee HY, Park H, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: state of the art. Eur J Radiol. 2017;86:297–307. doi:10.1016/j.ejrad.2016.09.005
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5(1):4006. doi:10.1038/ncomms5006
   PubMedGoogle Scholar
• Lee SH, Yim SY, Jeong YS, et al. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology. 2022;76(6):1634–1648. doi:10.1002/hep.32490
   Web of Science ®Google Scholar
• Shi JY, Wang X, Ding GY, et al. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. GUT. 2021;70(5):951–961. doi:10.1136/gutjnl-2020-320930
   Web of Science ®Google Scholar
• Saillard C, Schmauch B, Laifa O, et al. Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides. Hepatology. 2020;72(6):2000–2013. doi:10.1002/hep.31207
   Web of Science ®Google Scholar
• Wang H, Liu Y, Xu N, et al. Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. Eur J Radiol. 2022;156:110527. doi:10.1016/j.ejrad.2022.110527
   Web of Science ®Google Scholar
• Jung J, Joo JH, Kim SY, et al. Radiologic response as a prognostic factor in advanced hepatocellular carcinoma with macroscopic vascular invasion after transarterial chemoembolization and radiotherapy. Liver Can. 2021;11(2):152–161. doi:10.1159/000521227
   Web of Science ®Google Scholar
• Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology. 2020;72(1):198–212. doi:10.1002/hep.31022
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Serenari M, Sposito C, et al. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol. 2020;73(2):342–348. doi:10.1016/j.jhep.2020.03.018
   PubMed Web of Science ®Google Scholar
• Campani C, Vitale A, Dragoni G, et al. Time-varying mHAP-III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Liver Cancer. 2021;10(2):126–136. doi:10.1159/000513404
   Web of Science ®Google Scholar
• Park C, Kim JH, Kim PH, et al. Imaging predictors of survival in patients with single small hepatocellular carcinoma treated with transarterial chemoembolization. Korean J Radiol. 2021;22(2):213–224. doi:10.3348/kjr.2020.0325
   Web of Science ®Google Scholar
• Fu S, Lai H, Huang M, et al. Multi-task deep learning network to predict future macrovascular invasion in hepatocellular carcinoma. EClinicalMedicine. 2021;42:101201. doi:10.1016/j.eclinm.2021.101201
   Google Scholar
• Jiang Y, Zhang Z, Yuan Q, et al. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. Lancet Digit Health. 2022;4(5):e340–e350. doi:10.1016/S2589-7500(22)00040-1
   Google Scholar
• Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol. 2020;35(2):305–313. doi:10.1111/jgh.14816
   Web of Science ®Google Scholar
• Xu J, Qin S, Wei H, Chen Y, Peng Y, Qi L. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization. Anna Med. 2023;55(1):2199219. doi:10.1080/07853890.2023.2199219
   PubMed Web of Science ®Google Scholar
• Young L, Tabrizian P, Sung J, et al. Survival analysis using albumin-bilirubin (ALBI) grade for patients treated with drug-eluting embolic transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2022;33(5):510–517.e1. doi:10.1016/j.jvir.2022.02.005
   Web of Science ®Google Scholar
• Zhong B, Jiang J, Sun J, et al. Prognostic performance of the china liver cancer staging system in hepatocellular carcinoma following transarterial chemoembolization. J Clin Translat Hepatol. 2023;11(6):1321–1328. doi:10.14218/JCTH.2023.00099
   Web of Science ®Google Scholar